Patents by Inventor Jakob George

Jakob George has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF FTS FOR THE TREATMENT OF MYOCARDIAL ISCHEMIA/REPERFUSION INJURY
    Publication number: 20110130369
    Abstract: Disclosed are methods for reducing the extent of myocardial ischemia/reperfusion injury, comprising administering to a human prior to reperfusion of the ischemic myocardium or pre-angioplasty, coronary artery bypass surgery, or thrombolytic therapy an effective amount of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof. Methods of treating ischemia/reperfusion injury, comprising administering to a human after reperfusion of the ischemic myocardium or post-angioplasty, coronary artery bypass surgery, or thrombolytic therapy an effective amount of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof are also disclosed.
    Type: Application
    Filed: June 4, 2009
    Publication date: June 2, 2011
    Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Yoel Kloog, Jakob George, Gad Keren, Rakefet Pando
  • TREATMENT OF MYOCARDITIS USING FTS
    Publication number: 20100144873
    Abstract: Disclosed are methods of treating myocarditis by—administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 17, 2009
    Publication date: June 10, 2010
    Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventors: Yoel Kloog, Jakob George, Gad Keren, Rakefet Pando
  • Treatment of post-angioplasty restenosis and atherosclerosis with Ras antagonists
    Patent number: 6946485
    Abstract: Disclosed are methods for inhibiting Ras activity such as cell proliferation associated with vascular injury such as post-angioplasty restenosis and atherosclerosis. Preferred Ras antagonists are S-trans-trans farnesylthiosalicylic acid (FTS) and structurally related compounds (or analogs) thereof.
    Type: Grant
    Filed: April 22, 2003
    Date of Patent: September 20, 2005
    Assignee: Ramot at Tel Aviv University, Ltd.
    Inventors: Yoel Kloog, Gad Keren, Jakob George
  • Treatment of post-angioplasty restenosis and atherosclerosis with Ras antagonists
    Publication number: 20030203942
    Abstract: Disclosed are methods for inhibiting Ras activity such as cell proliferation associated with vascular injury such as post-angioplasty restenosis and atherosclerosis. Preferred Ras antagonists are S-trans-trans farnesylthiosalicylic acid (FTS) and structurally related compounds (or analogs) thereof.
    Type: Application
    Filed: April 22, 2003
    Publication date: October 30, 2003
    Applicant: Ramot at Tel Aviv University Ltd.
    Inventors: Yoel Kloog, Gad Keren, Jakob George
  • Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
    Publication number: 20020115696
    Abstract: Disclosed are methods for inhibiting Ras activity such as cell proliferation associated with vascular injury such as post-angioplasty restenosis and atherosclerosis. Preferred Ras antagonists are S-trans-trans farnesylthiosalicylic acid (FTS) and structurally related compounds (or analogs) thereof.
    Type: Application
    Filed: December 18, 2001
    Publication date: August 22, 2002
    Inventors: Yoel Kloog, Gad Keren, Jakob George